Chan, Andrew S.

[["dc.bibliographiccitation.firstpage","1170"],["dc.bibliographiccitation.issue","12"],["dc.bibliographiccitation.journal","Journal of Neurology Neurosurgery & Psychiatry"],["dc.bibliographiccitation.lastpage","1173"],["dc.bibliographiccitation.volume","83"],["dc.contributor.author","Decard, Bernhard F."],["dc.contributor.author","von Ahsen, Nicolas"],["dc.contributor.author","Grunwald, Thomas"],["dc.contributor.author","Streit, Frank"],["dc.contributor.author","Stroet, Anke"],["dc.contributor.author","Niggemeier, Petra"],["dc.contributor.author","Schottstedt, Volkmar"],["dc.contributor.author","Riggert, Joachim"],["dc.contributor.author","Gold, Ralf"],["dc.contributor.author","Chan, Andrew"],["dc.date.accessioned","2018-11-07T09:02:57Z"],["dc.date.available","2018-11-07T09:02:57Z"],["dc.date.issued","2012"],["dc.description.abstract","Objective Vitamin D deficiency and Epstein-Barr virus (EBV) infection may be associated with the development of multiple sclerosis (MS). We investigated serum 25-hydroxyvitamin D (25-OH-D) levels and anti-EBV immunoreactivity in 25 individuals before the first clinical manifestation of MS. Patients and methods 56 serum samples of 25 individuals who had donated blood prior to the first clinical MS manifestation (clinically isolated syndrome (CIS)) (four male subjects, 21 female subjects, mean age 31.5 years at time of pre-CIS blood sampling; mean age at disease onset 33.4 years) were available, covering an interval of 7.3 years-2 months (mean 31.5 months) before CIS. In 18 of 25 patients serum samples were also obtained after established diagnosis of MS. Longitudinal age- and gender-matched healthy blood donors (four male subjects, 21 female subjects, 39 samples, mean age 32.5 years) served as controls. Serum 25-OH-D was measured by isotope dilution-liquid chromatography-tandem mass spectrometry. 25-OH-D levels were deconvoluted using published seasonal coefficients from a German population. Immunoglobulin G (IgG) against Epstein-Barr virus nuclear antigen-1 (EBNA1) were assessed using commercially available ELISA. Results Low 25-OH-D levels were observed during the 24-month pre-CIS interval (47.8 (32.5-77.2) nmol/l, median (IQR); healthy controls: 81.6 (57.7-98.5), p=0.004, however, still higher than after established diagnosis (24.5 (13.7-47.7), p<0.0001 compared with controls). IgG against EBNA1 during the 36-month pre-CIS interval was increased (185.9 (91.2-460.0) IU/ml, median (IQR); healthy controls 63.7 (29.5-121.6), p=0.002). Conclusions Low vitamin D and remote EBV infection may be associated with clinical MS breakthrough within 2-3 years."],["dc.identifier.doi","10.1136/jnnp-2012-303068"],["dc.identifier.isi","000311097700012"],["dc.identifier.pmid","22888143"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/24794"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Bmj Publishing Group"],["dc.relation.issn","0022-3050"],["dc.title","Low vitamin D and elevated immunoreactivity against Epsteine-Barr virus before first clinical manifestation of multiple sclerosis"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","5356"],["dc.bibliographiccitation.issue","18"],["dc.bibliographiccitation.journal","Human Molecular Genetics"],["dc.bibliographiccitation.lastpage","5366"],["dc.bibliographiccitation.volume","24"],["dc.contributor.author","Zhang, C."],["dc.contributor.author","Doherty, Jennifer Anne"],["dc.contributor.author","Burgess, Stephen"],["dc.contributor.author","Hung, Rayjean J."],["dc.contributor.author","Lindstroem, Sara"],["dc.contributor.author","Kraft, Peter"],["dc.contributor.author","Gong, Jian"],["dc.contributor.author","Amos, Christopher I."],["dc.contributor.author","Sellers, Thomas A."],["dc.contributor.author","Monteiro, Alvaro N. A."],["dc.contributor.author","Chenevix-Trench, Georgia"],["dc.contributor.author","Bickeböller, Heike"],["dc.contributor.author","Risch, Angela"],["dc.contributor.author","Brennan, P. C."],["dc.contributor.author","McKay, James D."],["dc.contributor.author","Houlston, Richard S."],["dc.contributor.author","Landi, Maria Teresa"],["dc.contributor.author","Timofeeva, Maria N."],["dc.contributor.author","Wang, Y."],["dc.contributor.author","Heinrich, Joachim"],["dc.contributor.author","Kote-Jarai, Zsofia"],["dc.contributor.author","Eeles, Rosalind A."],["dc.contributor.author","Muir, Ken"],["dc.contributor.author","Wiklund, Fredrik"],["dc.contributor.author","Gronberg, Henrik"],["dc.contributor.author","Berndt, Sonja I."],["dc.contributor.author","Chanock, Stephen J."],["dc.contributor.author","Schumacher, Frederick R."],["dc.contributor.author","Haiman, Christopher A."],["dc.contributor.author","Henderson, Brian E."],["dc.contributor.author","Al Olama, Ali Amin"],["dc.contributor.author","Andrulis, Irene L."],["dc.contributor.author","Hopper, John L."],["dc.contributor.author","Chang-Claude, Jenny"],["dc.contributor.author","John, Esther M."],["dc.contributor.author","Malone, Kathleen E."],["dc.contributor.author","Gammon, Marilie D."],["dc.contributor.author","Ursin, Giske"],["dc.contributor.author","Whittemore, Alice S."],["dc.contributor.author","Hunter, David J."],["dc.contributor.author","Gruber, Stephen B."],["dc.contributor.author","Knight, Julia A."],["dc.contributor.author","Hou, Lifang"],["dc.contributor.author","Le Marchand, Loic"],["dc.contributor.author","Newcomb, Polly A."],["dc.contributor.author","Hudson, Thomas J."],["dc.contributor.author","Chan, Andrew T."],["dc.contributor.author","Li, L. I."],["dc.contributor.author","Woods, Michael O."],["dc.contributor.author","Ahsan, Habibul"],["dc.contributor.author","Pierce, Brandon L."],["dc.date.accessioned","2018-11-07T09:51:38Z"],["dc.date.available","2018-11-07T09:51:38Z"],["dc.date.issued","2015"],["dc.description.abstract","Epidemiological studies have reported inconsistent associations between telomere length (TL) and risk for various cancers. These inconsistencies are likely attributable, in part, to biases that arise due to post-diagnostic and post-treatment TL measurement. To avoid such biases, we used a Mendelian randomization approach and estimated associations between nine TL-associated SNPs and risk for five common cancer types (breast, lung, colorectal, ovarian and prostate cancer, including subtypes) using data on 51 725 cases and 62 035 controls. We then used an inverse-variance weighted average of the SNP-specific associations to estimate the association between a genetic score representing long TL and cancer risk. The long TL genetic score was significantly associated with increased risk of lung adenocarcinoma (P = 6.3 x 10(-15)), even after exclusion of a SNP residing in a known lung cancer susceptibility region (TERT-CLPTM1L) P = 6.6 x 10(-6)). Under Mendelian randomization assumptions, the association estimate [odds ratio (OR) = 2.78] is interpreted as the OR for lung adenocarcinoma corresponding to a 1000 bp increase in TL. The weighted TL SNP score was not associated with other cancer types or subtypes. Our finding that genetic determinants of long TL increase lung adenocarcinoma risk avoids issues with reverse causality and residual confounding that arise in observational studies of TL and disease risk. Under Mendelian randomization assumptions, our finding suggests that longer TL increases lung adenocarcinoma risk. However, caution regarding this causal interpretation is warranted in light of the potential issue of pleiotropy, and a more general interpretation is that SNPs influencing telomere biology are also implicated in lung adenocarcinoma risk."],["dc.identifier.doi","10.1093/hmg/ddv252"],["dc.identifier.isi","000361317200024"],["dc.identifier.pmid","26138067"],["dc.identifier.purl","https://resolver.sub.uni-goettingen.de/purl?gs-1/12147"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/35955"],["dc.notes.intern","Merged from goescholar"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Oxford Univ Press"],["dc.relation.issn","1460-2083"],["dc.relation.issn","0964-6906"],["dc.rights","CC BY 4.0"],["dc.rights.uri","https://creativecommons.org/licenses/by/4.0"],["dc.title","Genetic determinants of telomere length and risk of common cancers: a Mendelian randomization study"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dc.type.version","published_version"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","991"],["dc.bibliographiccitation.issue","12"],["dc.bibliographiccitation.journal","Neurology"],["dc.bibliographiccitation.lastpage","993"],["dc.bibliographiccitation.volume","73"],["dc.contributor.author","Doerr, J."],["dc.contributor.author","Bitsch, Annette"],["dc.contributor.author","Schmailzl, K. J. G."],["dc.contributor.author","Chan, A."],["dc.contributor.author","von Ahsen, Nicolas"],["dc.contributor.author","Hummel, Michael"],["dc.contributor.author","Varon, R."],["dc.contributor.author","Lill, C. M."],["dc.contributor.author","Vogel, H.-P."],["dc.contributor.author","Zipp, Frauke"],["dc.contributor.author","Paul, Friedemann"],["dc.date.accessioned","2018-11-07T11:24:13Z"],["dc.date.available","2018-11-07T11:24:13Z"],["dc.date.issued","2009"],["dc.identifier.doi","10.1212/WNL.0b013e3181b878f6"],["dc.identifier.isi","000270035000013"],["dc.identifier.pmid","19770476"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/56354"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Lippincott Williams & Wilkins"],["dc.relation.issn","0028-3878"],["dc.title","SEVERE CARDIAC FAILURE IN A PATIENT WITH MULTIPLE SCLEROSIS FOLLOWING LOW-DOSE MITOXANTRONE TREATMENT"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dc.type.subtype","letter_note"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","22"],["dc.bibliographiccitation.journal","Journal of Neurology"],["dc.bibliographiccitation.lastpage","27"],["dc.bibliographiccitation.volume","255"],["dc.contributor.author","Chan, Andrew"],["dc.contributor.author","Stueve, Olaf"],["dc.contributor.author","von Ahsen, Nicolas"],["dc.date.accessioned","2018-11-07T11:08:39Z"],["dc.date.available","2018-11-07T11:08:39Z"],["dc.date.issued","2008"],["dc.description.abstract","Despite novel immunoactive agents, immunosuppressants still play a considerable role in the treatment of MS, especially in rapidly progressive cases. Given the limited tolerability and potentially severe side effects of most immunosuppressive drugs, identification of patients with a favorable benefit-risk profile is essential. A narrow therapeutic index, with sometimes high interindividual variability in terms of response and side effects may partially be explained by genetic factors affecting different metabolic pathways. Here, we will review practical aspects in the clinical use of immunosuppressants in MS and discuss approaches to individualized treatment schemes, including novel pharmacogenetic strategies."],["dc.identifier.doi","10.1007/s00415-008-6005-y"],["dc.identifier.isi","000263166600005"],["dc.identifier.pmid","19300956"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/52835"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Dr Dietrich Steinkopff Verlag"],["dc.relation.issn","0340-5354"],["dc.title","Immunosuppression in clinical practice Approaches to individualized therapy"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.artnumber","e85"],["dc.bibliographiccitation.issue","3"],["dc.bibliographiccitation.journal","Neurology® neuroimmunology & neuroinflammation"],["dc.bibliographiccitation.volume","2"],["dc.contributor.author","Hoepner, Robert"],["dc.contributor.author","Faissner, Simon"],["dc.contributor.author","Klasing, Anja"],["dc.contributor.author","Schneider, Ruth"],["dc.contributor.author","Metz, Imke"],["dc.contributor.author","Bellenberg, Barbara"],["dc.contributor.author","Lukas, Carsten"],["dc.contributor.author","Altmeyer, Peter"],["dc.contributor.author","Gold, Ralf"],["dc.contributor.author","Chan, Andrew"],["dc.date.accessioned","2016-08-23T08:49:19Z"],["dc.date.accessioned","2021-10-27T13:20:42Z"],["dc.date.available","2016-08-23T08:49:19Z"],["dc.date.available","2021-10-27T13:20:42Z"],["dc.date.issued","2015-06-01"],["dc.description.abstract","not available"],["dc.identifier.doi","10.1212/NXI.0000000000000085"],["dc.identifier.fs","611967"],["dc.identifier.pmid","25798449"],["dc.identifier.purl","https://resolver.sub.uni-goettingen.de/purl?gs-1/13596"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/91978"],["dc.language.iso","en"],["dc.notes.intern","Migrated from goescholar"],["dc.relation.issn","2332-7812"],["dc.relation.orgunit","Universitätsmedizin Göttingen"],["dc.rights","CC BY-NC-ND 3.0"],["dc.rights.uri","https://creativecommons.org/licenses/by-nc-nd/3.0"],["dc.title","Progressive multifocal leukoencephalopathy during fumarate monotherapy of psoriasis."],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.version","published_version"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","2517"],["dc.bibliographiccitation.journal","Brain"],["dc.bibliographiccitation.lastpage","2530"],["dc.bibliographiccitation.volume","132"],["dc.contributor.author","Cotte, S."],["dc.contributor.author","von Ahsen, Nicolas"],["dc.contributor.author","Kruse, Niels"],["dc.contributor.author","Huber, B."],["dc.contributor.author","Winkelmann, Alexander"],["dc.contributor.author","Zettl, Uwe K."],["dc.contributor.author","Starck, Michaela"],["dc.contributor.author","Koenig, N."],["dc.contributor.author","Tellez, N."],["dc.contributor.author","Doerr, J."],["dc.contributor.author","Paul, Friedemann"],["dc.contributor.author","Zipp, Frauke"],["dc.contributor.author","Luehder, Fred"],["dc.contributor.author","Koepsell, Hermann"],["dc.contributor.author","Pannek, H."],["dc.contributor.author","Montalban, Xavier"],["dc.contributor.author","Gold, Ralf"],["dc.contributor.author","Chan, A."],["dc.date.accessioned","2018-11-07T11:24:34Z"],["dc.date.available","2018-11-07T11:24:34Z"],["dc.date.issued","2009"],["dc.description.abstract","Escalation therapy with mitoxantrone (MX) in highly active multiple sclerosis is limited by partially dose-dependent side-effects. Predictors of therapeutic response may result in individualized risk stratification and MX dosing. ATP-binding cassette-transporters ABCB1 and ABCG2 represent multi-drug resistance mechanisms involved in active cellular MX efflux. Here, we investigated the role of ABC-gene single nucleotide polymorphisms (SNPs) for clinical MX response, corroborated by experimental in vitro and in vivo data. Frequencies of ABCB1 2677GT, 3435CT and five ABCG2-SNPs were analysed in 832 multiple sclerosis patients (Germany, Spain) and 264 healthy donors. Using a flow-cytometry-based in vitro assay, MX efflux in leukocytes from individuals with variant alleles in both ABC-genes (designated genotype ABCB1/ABCG2-L(ow), 22.2 of patients) was 37.7 lower than from individuals homozygous for common alleles (ABCB1/ABCG2-H(igh), P 0.05, 14.8 of patients), resulting in genotype-dependent MX accumulation and cell death. Addition of glucocorticosteroids (GCs) inhibited MX efflux in vitro. ABC-transporters were highly expressed in leukocyte subsets, glial and neuronal cells as well as myocardium, i.e. cells/tissues potentially affected by MX therapy. In vivo significance was further corroborated in experimental autoimmune encephalomyelitis in Abcg2(/) animals. Using a MX dose titrated to be ineffective in wild-type animals, disease course and histopathology in Abcg2(/) mice were strongly ameliorated. Retrospective clinical analysis in MX monotherapy patients (n 155) used expanded disability status scale, relapse rate and multiple sclerosis functional composite as major outcome parameters. The clinical response rate [overall 121 of 155 patients (78.1)] increased significantly with genotypes associated with decreasing ABCB1/ABCG2-function [ABCB1/ABCG2-H 15/24 (62.5) responders, ABCB1/ABCG2-I(ntermediate) 78/98 (79.6), ABCB1/ABCG2-L 28/33 (84.8), exact Cochran-Armitage test P 0.039]. The odds ratio for response was 1.9 (95 CI 1.03.5) with each increase in ABCB1/ABCG2 score (from ABCB1/ABCG2-H to I-, and I to L). In 36 patients with severe cardiac or haematological side effects no statistically relevant difference in genotype frequency was observed. However, one patient with biopsy proven cardiomyopathy only after 24 mg/m(2) MX exhibited a rare genotype with variant, partly homozygous alleles in 3 ABC-transporter genes. In conclusion, SNPs in ABC-transporter genes may serve as pharmacogenetic markers associated with clinical response to MX therapy in multiple sclerosis. Combined MX/GC-treatment warrants further investigation."],["dc.description.sponsorship","Merck Serono, Germany"],["dc.identifier.doi","10.1093/brain/awp164"],["dc.identifier.isi","000269963600021"],["dc.identifier.pmid","19605531"],["dc.identifier.purl","https://resolver.sub.uni-goettingen.de/purl?gs-1/6073"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/56436"],["dc.notes.intern","Merged from goescholar"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Oxford Univ Press"],["dc.relation.issn","0006-8950"],["dc.rights","Goescholar"],["dc.rights.uri","https://goescholar.uni-goettingen.de/licenses"],["dc.title","ABC-transporter gene-polymorphisms are potential pharmacogenetic markers for mitoxantrone response in multiple sclerosis"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","2803"],["dc.bibliographiccitation.issue","26"],["dc.bibliographiccitation.journal","Current Pharmaceutical Design"],["dc.bibliographiccitation.lastpage","2807"],["dc.bibliographiccitation.volume","17"],["dc.contributor.author","Chan, A."],["dc.contributor.author","Gold, Ralf"],["dc.contributor.author","von Ahsen, Nicolas"],["dc.date.accessioned","2018-11-07T08:51:51Z"],["dc.date.available","2018-11-07T08:51:51Z"],["dc.date.issued","2011"],["dc.description.abstract","Owing to therapeutic progress, the role of ABC-transporters in infectious and autoimmune inflammatory CNS-diseases has recently gained considerable attention. In HIV-encephalitis and HIV-associated neurocognitive disorders, ABC-transporters are discussed to contribute to limited CNS-penetration and -retention of antiviral agents. In multiple sclerosis and its animal model experimental autoimmune encephalomyelitis, ABC-transporters may be involved in pathogenesis and treatment response alike. A prospective pharmacogenetic study is currently underway to examine the predictive role of genetic variations in ABC-transporters for treatment response and adverse events to mitoxantrone, a therapeutic agent used in aggressive MS. These approaches may aid in individualized treatment with this cytostatic anthracenedione, addressing its narrow therapeutic index with potentially fatal side effects. Finally, understanding regulation and function of ABC-transporters under inflammatory conditions may also optimize ABC-transporter-related treatment strategies in other neurological diseases (e. g. neurodegenerative, and neurovascular) where neuroinflammatory mechanisms have gained considerable attention as important contributors to pathogenesis."],["dc.identifier.isi","000299630800009"],["dc.identifier.pmid","21827405"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/22032"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Bentham Science Publ Ltd"],["dc.relation.issn","1381-6128"],["dc.title","ATP-Binding Cassette Transporters in Inflammatory Brain Disease"],["dc.type","review"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","277"],["dc.bibliographiccitation.journal","Journal of Neuroimmunology"],["dc.bibliographiccitation.lastpage","279"],["dc.bibliographiccitation.volume","278"],["dc.contributor.author","Grey (nee Cotte), Steffi"],["dc.contributor.author","Salmen (nee Stroet), Anke"],["dc.contributor.author","von Ahsen, Nico"],["dc.contributor.author","Starck, Michaela"],["dc.contributor.author","Winkelmann, Alexander"],["dc.contributor.author","Zettl, Uwe K."],["dc.contributor.author","Comabella, Manuel"],["dc.contributor.author","Montalban, Xavier"],["dc.contributor.author","Zipp, Frauke"],["dc.contributor.author","Fleischer, Vinzenz"],["dc.contributor.author","Kruse, Niels"],["dc.contributor.author","Gold, Ralf"],["dc.contributor.author","Chan, Andrew"],["dc.date.accessioned","2018-11-07T10:02:07Z"],["dc.date.available","2018-11-07T10:02:07Z"],["dc.date.issued","2015"],["dc.description.abstract","Background: Mitoxantrone is used on an off-label basis in primary progressive MS (PPMS).ABC-transporter-genotypes are associated with therapeutic response in relapsing/secondary progressive MS (RP/SPMS). Objective: To evaluate potential pharmacogenetic response markers for mitoxantrone in PPMS. Methods: 41 mitoxantrone-treated PPMS-patients, 155 mitoxantrone-treated RP/SPMS-patients and 43 PPMS-controls were retrospectively assessed for clinical therapy-response and in correlation with four single-nucleotide-polymorphisms in ABCB1- and ABCG2-genes. Results: 53.7% PPMS-patients were mitoxantrone-responders, in comparison to 78.1% of RP/SPMS-patients (p = 0.039). There was no association between genotype and treatment response. Conclusion: Our data discourages the use of mitoxantrone in PPMS regardless of pharmacogenetic response markers previously described in RP/SPMS. (C) 2014 Elsevier B.V. All rights reserved."],["dc.identifier.doi","10.1016/j.jneuroim.2014.11.017"],["dc.identifier.isi","000349269300035"],["dc.identifier.pmid","25468777"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/38167"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Elsevier Science Bv"],["dc.relation.issn","1872-8421"],["dc.relation.issn","0165-5728"],["dc.title","Lack of efficacy of mitoxantrone in primary progressive Multiple Sclerosis irrespective of pharmacogenetic factors: A multi-center, retrospective analysis"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","165"],["dc.bibliographiccitation.journal","Multiple Sclerosis Journal"],["dc.bibliographiccitation.lastpage","166"],["dc.bibliographiccitation.volume","22"],["dc.contributor.author","Schrewe, L."],["dc.contributor.author","Meyer, D."],["dc.contributor.author","Boehme, A."],["dc.contributor.author","Pittlik, S. M."],["dc.contributor.author","Demir, Seray"],["dc.contributor.author","Faissner, S."],["dc.contributor.author","Hagemann, N."],["dc.contributor.author","Schmidt, D."],["dc.contributor.author","Hermann, Dirk M."],["dc.contributor.author","Luehder, Fred"],["dc.contributor.author","Chan, A."],["dc.date.accessioned","2018-11-07T10:08:47Z"],["dc.date.available","2018-11-07T10:08:47Z"],["dc.date.issued","2016"],["dc.description.sponsorship","Genzyme; Novartis; Biogen; Teva; Bayer; Merck; Roche; Teva Neuroscience"],["dc.identifier.isi","000383267201143"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/39535"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Sage Publications Ltd"],["dc.publisher.place","London"],["dc.relation.conference","32nd Congress of the European-Committee-for-Treatment-and-Research-in-Multiple-Sclerosis (ECTRIMS)"],["dc.relation.eventlocation","London, ENGLAND"],["dc.relation.issn","1477-0970"],["dc.relation.issn","1352-4585"],["dc.title","Apolipoprotein E modulates abcg2 transporter expression and function in the context of teriflunomide-therapy of experimental autoimmune encephalomyelitis"],["dc.type","conference_abstract"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","1604"],["dc.bibliographiccitation.issue","11"],["dc.bibliographiccitation.journal","Journal of Neurology"],["dc.bibliographiccitation.lastpage","1606"],["dc.bibliographiccitation.volume","254"],["dc.contributor.author","Chan, Andrew"],["dc.contributor.author","Lee, De-Hyung"],["dc.contributor.author","Linker, Ralf"],["dc.contributor.author","Mohr, Alexander"],["dc.contributor.author","Toyka, Klaus V."],["dc.contributor.author","Gold, Ralf"],["dc.date.accessioned","2018-11-07T10:57:12Z"],["dc.date.available","2018-11-07T10:57:12Z"],["dc.date.issued","2007"],["dc.identifier.doi","10.1007/s00415-007-0593-9"],["dc.identifier.isi","000251096000021"],["dc.identifier.pmid","17713826"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/50186"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Dr Dietrich Steinkopff Verlag"],["dc.relation.issn","0340-5354"],["dc.title","Rescue therapy with anti-CD20 treatment in neuroimmunologic breakthrough disease"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dc.type.subtype","letter_note"],["dspace.entity.type","Publication"]]